CV Sciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
CVSIStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Product sales, net | $3,865 | $4,089 | $11,821 | $12,203 |
| Cost of goods sold | 2,087 | 2,246 | 6,330 | 6,860 |
| Gross profit | 1,778 | 1,843 | 5,491 | 5,343 |
| Operating expenses: | ||||
| Research and development | 29 | 40 | 93 | 111 |
| Selling, general and administrative | 2,090 | 2,240 | 6,942 | 7,154 |
| Benefit from reversal of accrued payroll taxes (Note 12) | — | — | — | (6,171) |
| Total operating expenses | 2,119 | 2,280 | 7,035 | 1,094 |
| Operating income (loss) | (341) | (437) | (1,544) | 4,249 |
| Other expense, net | 115 | 10 | 118 | 275 |
| Income (loss) before income taxes | (456) | (447) | (1,662) | 3,974 |
| Income tax expense | — | — | 6 | 3 |
| Net income (loss) | $(456) | $(447) | $(1,668) | $3,971 |
| Weighted average common shares outstanding, basic and diluted | 182,261 | 154,604 | 172,671 | 153,112 |
| Net income (loss) per common share, basic and diluted | $(0.00) | $(0.00) | $(0.01) | $0.03 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.